相似文献
1
Lymphatic metastasis in non-small cell lung cancer: recent discoveries and novel therapeutic targets.非小细胞肺癌中的淋巴转移：最新发现与新型治疗靶点
Cancer Commun (Lond). 2022 Dec;42(12):1403-1406. doi: 10.1002/cac2.12378. Epub 2022 Nov 9.
2
In regard to Rosenzweiz et al. IJROBP 2001;50:681-685.关于罗森茨魏格等人的研究，《国际放射肿瘤学、生物学、物理学杂志》2001年；第50卷：第681 - 685页。
Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):878. doi: 10.1016/s0360-3016(01)02650-5.
3
The prognostic value of residual mediastinal involvement following induction therapy and surgery for locally advanced non-small cell lung cancer.诱导治疗和手术后残留纵隔受累对局部晚期非小细胞肺癌的预后价值。
Lung Cancer. 2004 Oct;46(1):125-6; author reply 127-8. doi: 10.1016/j.lungcan.2004.03.019.
4
[Therapy for non-small-cell lung carcinoma (NSCLC) in stage IV].[IV期非小细胞肺癌（NSCLC）的治疗]
Onkologie. 2006 Sep;29 Suppl 2:15-9. doi: 10.1159/000094950. Epub 2006 Sep 6.
5
[Progress on study of TCM prevention and treatment of post operational relapse and metastasis of lung cancer].[中医防治肺癌术后复发转移的研究进展]
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003 Oct;23(10):797-800.
6
Commentary: Chemotherapy Before or After Surgery in Patients With Single Station N2 Non-Small Cell Lung Cancer: One Size Does Not Fit All.评论：单站N2期非小细胞肺癌患者手术前还是手术后进行化疗：一刀切并不适用。
Semin Thorac Cardiovasc Surg. 2021 Spring;33(1):219-220. doi: 10.1053/j.semtcvs.2020.10.024. Epub 2020 Nov 9.
7
Is there a definitive answer to the question of involved-field radiotherapy for inoperable non-small-cell lung cancer?对于无法手术的非小细胞肺癌的累及野放疗问题，是否有明确的答案？
J Clin Oncol. 2008 May 1;26(13):2235; author reply 2235-6. doi: 10.1200/JCO.2008.16.3436.
8
[Surgical therapy of locally advanced non-small cell lung carcinoma].[局部晚期非小细胞肺癌的外科治疗]
Chir Ital. 1995;47(3):30-3.
9
A case of residual non-small cell lung cancer cells coexisting with newly developed small cell lung cancer cells in ascitic fluid after chemotherapy for non-small cell lung cancer.一例非小细胞肺癌化疗后腹水中残留的非小细胞肺癌细胞与新出现的小细胞肺癌细胞共存的病例。
Ann Lab Med. 2014 Mar;34(2):163-5. doi: 10.3343/alm.2014.34.2.163. Epub 2014 Feb 13.
10
Surgery in stage III non-small-cell lung cancer.Ⅲ期非小细胞肺癌的外科治疗
Lancet. 2009 Aug 1;374(9687):359-60. doi: 10.1016/S0140-6736(09)61026-6. Epub 2009 Jul 24.
引用本文的文献
1
IGF2BP3 Triggers STAT3 Pathway by Stabilizing SRC RNA in an m6A-Dependent Manner to Promote Lymphatic Metastasis in LUAD.IGF2BP3通过以m6A依赖的方式稳定SRC RNA触发STAT3信号通路，促进肺腺癌的淋巴转移。
Cancer Sci. 2025 Apr;116(4):936-950. doi: 10.1111/cas.16451. Epub 2025 Jan 13.
2
Oncogenic circ-SLC16A1 promotes progression of non-small cell lung cancer via regulation of the miR-1287-5p/profilin 2 axis.致癌性环状 SLC16A1 通过调节 miR-1287-5p/丝状蛋白 2 轴促进非小细胞肺癌的进展。
Cell Mol Biol Lett. 2024 Mar 27;29(1):43. doi: 10.1186/s11658-024-00549-x.
3
Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study.完全切除的I-IIIA期非小细胞肺癌患者微小残留病阳性的相关性分析：一项队列研究
Front Oncol. 2023 Jul 21;13:1222716. doi: 10.3389/fonc.2023.1222716. eCollection 2023.
4
Nicotinamide adenine dinucleotide kinase promotes lymph node metastasis of NSCLC via activating ID1 expression through BMP pathway.烟酰胺腺嘌呤二核苷酸激酶通过激活 BMP 通路促进非小细胞肺癌淋巴结转移。
Int J Biol Sci. 2023 Jun 19;19(10):3184-3199. doi: 10.7150/ijbs.84322. eCollection 2023.
本文引用的文献
1
Characterization of the MicroRNA Cargo of Extracellular Vesicles Isolated from a Pulmonary Tumor-Draining Vein Identifies miR-203a-3p as a Relapse Biomarker for Resected Non-Small Cell Lung Cancer.从肺肿瘤引流静脉中分离的外泌体的 microRNA cargos 的特征分析确定 miR-203a-3p 为切除的非小细胞肺癌复发的生物标志物。
Int J Mol Sci. 2022 Jun 27;23(13):7138. doi: 10.3390/ijms23137138.
2
Lymph node micrometastasis in non-small cell lung cancer.非小细胞肺癌中的淋巴结微转移
Biomed Pharmacother. 2022 May;149:112817. doi: 10.1016/j.biopha.2022.112817. Epub 2022 Mar 15.
3
Genomic Evolution of Lung Cancer Metastasis: Current Status and Perspectives.肺癌转移的基因组进化：现状与展望
Cancer Commun (Lond). 2021 Dec;41(12):1252-1256. doi: 10.1002/cac2.12237. Epub 2021 Nov 29.
4
Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020.中国癌症发病率、死亡率和疾病负担的变化趋势分析：基于 2020 年全球公布的流行病学数据与美国和英国的比较
Cancer Commun (Lond). 2021 Oct;41(10):1037-1048. doi: 10.1002/cac2.12197. Epub 2021 Jul 20.
5
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
6
Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling.安罗替尼通过可能涉及 VEGFR-3 信号通路的过程抑制肺腺癌中的淋巴管生成和淋巴转移。
Cancer Biol Med. 2020 Aug 15;17(3):753-767. doi: 10.20892/j.issn.2095-3941.2020.0024.
7
Identification of Three Circular RNA Cargoes in Serum Exosomes as Diagnostic Biomarkers of Non-Small-Cell Lung Cancer in the Chinese Population.鉴定中国人血清外泌体中的三种环状 RNA cargos 作为非小细胞肺癌的诊断生物标志物。
J Mol Diagn. 2020 Aug;22(8):1096-1108. doi: 10.1016/j.jmoldx.2020.05.011. Epub 2020 Jun 12.
8
Cancer burden of major cancers in China: A need for sustainable actions.中国主要癌症的癌症负担：需要采取可持续行动。
Cancer Commun (Lond). 2020 May;40(5):205-210. doi: 10.1002/cac2.12025. Epub 2020 May 2.
9
CCBE1 promotes tumor lymphangiogenesis and is negatively regulated by TGFβ signaling in colorectal cancer.CCBE1 促进结直肠癌中的肿瘤淋巴管生成，并受 TGFβ 信号通路的负调控。
Theranostics. 2020 Jan 16;10(5):2327-2341. doi: 10.7150/thno.39740. eCollection 2020.
10
Serum exosomal miR-378 upregulation is associated with poor prognosis in non-small-cell lung cancer patients.血清外泌体 miR-378 上调与非小细胞肺癌患者预后不良相关。
J Clin Lab Anal. 2020 Jun;34(6):e23237. doi: 10.1002/jcla.23237. Epub 2020 Feb 14.
Zotero 插件